



**SUPRIYA LIFESCIENCE LTD.**

*Creating true values that bind global health*

November 13, 2025

To,

BSE Limited  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai- 400 001  
**Scrip Code: 543434**

National Stock Exchange of India Limited  
Exchange Plaza, Plot no. C/1, G Block,  
Bandra-Kurla Complex  
Bandra (E), Mumbai - 400 051  
**NSE Symbol: SUPRIYA**

Dear Sir/Madam,

**Subject: Press Release- Unaudited Financial Results for the Quarter and Half Year ended September 30, 2025.**

The Board of Directors of the Company at their Meeting held on November 12, 2025 has inter alia, considered and approved the Unaudited Financial Results for the quarter and half year ended September 30, 2025.

Please find attached the Press Release regarding the Unaudited Financial Results of the Company for the Quarter and Half Year ended September 30, 2025.

Kindly take the same on record.

Thanking you,

**For Supriya Lifescience Limited**

**Prachi Sathe**  
**Company Secretary & Compliance Officer**

---

**Corporate office** : 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai – 400 063. Maharashtra, India.  
Tel: +91 22 40332727 / 66942507 Fax : +91 22 26860011 GSTIN: 27AALCS8686A1ZX  
CIN: L51900MH2008PLC180452 E-mail: [supriya@supriyalifescience.com](mailto:supriya@supriyalifescience.com) Website:  
[www.supriyalifescience.com](http://www.supriyalifescience.com)

**Factory** : A-5/2, Lote Parshuram Industrial Area, M.I.D.C. Tal.– Khed, Dist. – Ratnagiri, Pin :415 722, Maharashtra, India.  
Tel: +91 2356 272299 Fax: +91 2356 272178 E-mail: [factory@supriyalifescience.com](mailto:factory@supriyalifescience.com)

**GOVT. RECOGNISED EXPORT HOUSE**



## SUPRIYA LIFESCIENCE LTD.

### Press Release for immediate distribution

### **Supriya Lifescience Delivers Strong Q2 FY26 Performance with 20.3% YoY Revenue Growth**

**Mumbai, 13<sup>th</sup> November 2025:** The unaudited financial statements for Q2FY26 have been released by Supriya Lifescience Ltd., a cGMP-compliant business with a strong track record in API manufacturing and a focus on products from a variety of therapeutic segments, including anti-histamine, anti-allergic, vitamin, anaesthetic, and anti-asthmatic. The company has spread its business in more than 120 countries across the globe.

#### **Key Consolidated Financial Highlights:**

Particulars	Q2 FY26	Q2 FY25
Revenues (in Rs Cr)	199.83	166.10
EBITDA (in Rs Cr)	72.65	64.72
EBITDA Margin	36.4%	39.0%
PAT (in RsCr)	50.43	46.15
PAT Margin	25.2%	27.8%
Quarterly EPS (in Rs)	6.27	5.71

#### **Key Highlights for Q2 FY26:**

In Q2 FY26, Supriya Lifescience Ltd. witnessed a 20.3 % year-over-year growth in Revenue to Rs 199.83 crore compared to Rs 166.10 crore in Q2 FY25.

EBITDA for Q2 FY26 stood at Rs. 72.65 crore, with an EBITDA margin of 36.4%, as against Rs 64.72 crore in Q2 FY25 with a margin of 39.0%.

The Profit After Tax (PAT) for Q2 FY26 was Rs 50.43 crore, compared to Rs 46.15 crore in Q2 FY25.

The PAT Margin stood at 25.2% in Q2 FY26 versus 27.8% in Q2 FY25.

The anesthetic segment led the revenue growth in H1 FY26, contributing 54% to the revenue vs 46% in H1 FY25. The contribution of the Anti-histamine segment rose from 10% to 12%, while that of the Vitamin segment also improved from 11% to 12% during H1FY26 compared to H1FY25.

European markets continue to lead with a contribution of 37% of our business revenue in Q2 FY26, While the share of Asia as well as LATAM markets have improved both sequentially as well as Year-on-Year. Asia accounts for 34% of revenue in Q2FY26 as compared to 32% in Q1FY26, while Latin American markets contributed 21% in Q2FY26, up from 17% in Q1FY26

Capacity Utilisation has recovered from 70% in FY25 to 78 % in H1FY26. In order to support the future growth of various business segments, the company has acquired three separate land parcels near different plants.

**Mr. Satish Wagh, Chairman and Whole Time Director, Supriya Lifescience Ltd**, commenting on the results, said, *“Our second quarter reflects a healthy recovery in Revenue and sustained profitability, supported by steady demand across key markets. Exports accounted for around 81% of Q2 FY26 revenues, with Europe contributing around 40% of the total business mix. Capacity utilisation improved to approximately 78% in H1FY26, aided by the ramp-up of the newly commissioned Module E at our Lote Parshuram facility, which has strengthened operational efficiency and stability. With the upcoming commercial launch of our Ambernath formulation facility in H2 FY26 and continued focus on regulated markets, backward integration and new product introductions, we are confident of delivering stronger growth in the second half of the year.”*

.....

**Disclaimer Statements** in this “Document” describing the company’s objectives, projections, estimates, expectations, plans or predictions, or industry conditions or events may be "forward-looking statements" within the meaning of applicable securities laws and regulations. Actual results, performance, or achievements could differ materially from those expressed or implied. The Company undertakes no obligation to update or revise forward-looking statements to reflect developments or circumstances that arise or to reflect the occurrence of unanticipated developments or circumstances after the date hereof.

**About Supriya Lifescience Ltd.:**

Supriya Lifescience Ltd., a world-renowned producer of active pharmaceutical ingredients, was founded in 1987. Our state-of-the-art facility has certifications from Health Canada, EUGMP, EDQM, USFDA, and NMPA. The company is headquartered in Mumbai, India, and our facility is located in Khed, District Ratnagiri. Our globally compliant facilities USFDA, EDQM, WHO, PMDA, KFDA and ANVISA are supported by robust R&D, eight active CEPs, and fourteen active USDMFs. EHS requirements and ethical principles guide our core business. The company's primary focus is to build intermediates and APIs for innovators and generic firms. We also exclusively collaborate with partners in the capacity of CMOs.

For more details, contact:

Abhishek Chawande: [Abhishek.Chawande@dentsu.com](mailto:Abhishek.Chawande@dentsu.com) | 9664516774

Sanjukta Ghadge: [Sanjukta.ghadge@dentsu.com](mailto:Sanjukta.ghadge@dentsu.com) | 98926 89895